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Abstract: Patients admitted to hospital with coronavirus disease 2019 (COVID-19) may develop 
acute respiratory failure (ARF) with compromised gas exchange. These patients require oxygen and 
possibly ventilatory support, which can be delivered via different devices. Initially, oxygen therapy 
will often be administered through a conventional binasal oxygen catheter or air-entrainment mask. 
However, when higher rates of oxygen flow are needed, patients are often stepped up to high-flow 
nasal cannula oxygen therapy (HFNC), continuous positive airway pressure (CPAP), bilevel posi-
tive airway pressure (BiPAP), or invasive mechanical ventilation (IMV). BiPAP, CPAP, and HFNC 
may be beneficial alternatives to IMV for COVID-19-associated ARF. Current evidence suggests that 
when nasal catheter oxygen therapy is insufficient for adequate oxygenation of patients with 
COVID-19-associated ARF, CPAP should be provided for prolonged periods. Subsequent escalation 
to IMV may be implemented if necessary. 
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Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) may develop coronavirus disease 2019 (COVID-19) with viral pneumonia, acute respir-
atory failure (ARF), or acute respiratory distress syndrome (ARDS) and may require hos-
pital admission [1–3]. ARF is defined as the inability of the respiratory system to meet the 
oxygenation demands, ventilation, or metabolic requirements of the patient [4]. Treating 
patients with COVID-19 who have ARF involves oxygen supplementation and, in some 
cases, a degree of assisted ventilation. In the most severe cases of hypoxemia, invasive 
mechanical ventilation (IMV) may be necessary. However, access to IMV therapy may be 
limited, and this should be reserved for cases in which it is clearly indicated. IMV can 
result in complications linked to the intubation procedure and increased risks of ventila-
tor-induced lung injury and ventilator-associated pneumonia, as well as long-term com-
plications such as critical illness polyneuromyopathy [5–7]. Consequently, many intensive 
care units (ICUs) and nonintensive care medical departments looked for alternatives to 
IMV during the initial surge in COVID-19 cases. These alternatives included bilevel posi-
tive airway pressure (BiPAP), continuous positive airway pressure (CPAP), and high-flow 
nasal cannula oxygen therapy (HFNC). One substantial benefit of IMV is that it operates 
within a closed system, resulting in minimal spread of viral particles. Some clinicians were 
reluctant to use BiPAP, CPAP, and HFNC during the initial phase of the COVID-19 pan-
demic, due to the potential risk of transmission to healthcare staff [8–10]. The different 
types of ventilation treatment are associated with different risks of particle dispersion and 
disease transmission. Studies have shown that CPAP is not associated with significant 
leakage of exhaled air, whereas a single BiPAP circuit resulted in exhaled air reaching a 
distance up to 0.92 m from the BiPAP apparatus [11]. Similarly, a double BiPAP circuit 
was not associated with significant leakage. It may be relevant to compare the associated 
risks when ARF treatment efficacies are similar; however, as a German study stated, fear 
of transmission must not become the basis for selecting which ventilation method to use 
for patients [12]. Therefore, determining the best treatment options and alternative venti-
lation methods for patients with COVID-19 is critical. This review investigates the current 
treatment of patients with COVID-19 and ARF, as well as relevant ventilation strategies. 
2. Acute Respiratory Failure and COVID-19 
ARF can be categorized as type I or type II. Type I ARF is characterized by hypoxemia 
with a reduced partial pressure of oxygen in arterial blood (PaO2). This is the type of res-
piratory failure most frequently observed in patients with COVID-19 who have had no 
prior respiratory illness or have had low levels of exposure to tobacco smoke [2]. Type II 
ARF is characterized by hypercapnia with an increased partial pressure of CO2 in arterial 
blood (PaCO2) [13]. Patients with hypoxemic (type I) and hypercapnic (type II) ARF may 
benefit from different oxygenation strategies, to minimize the risk of deterioration and the 
requirement for IMV [14]. Evidence is accumulating that the course of hypoxemic lung 
injury in COVID-19 pneumonia may be more heterogeneous and may differ in various 
ways from the course of the disease in other pathogenic contexts [15,16]. In COVID-19 
pneumonia, hypoxemic lung injury is accompanied by damage to the vascular endothe-
lium and an increased risk of multiple organ failure. Therefore, COVID-19 pneumonia can 
be viewed as a systemic disease [12]. 
3. Oxygenation Targets for Patients with COVID-19 and Respiratory Symptoms 
The HOT ICU trial, a randomized controlled trial (RCT) of 2928 patients, demon-
strated that patients with ARF do not benefit from a target PaO2 of 60 mm Hg in compar-
ison to target PaO2 of 90 mm Hg [17]. A smaller RCT found that in patients with ARDS 
but no exposure to SARS-CoV-2, liberal oxygen therapy (i.e., targeting peripheral oxygen 
saturation (SpO2) of >96%) did not increase survival at 28 days, compared with conserva-
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tive oxygen therapy (i.e., targeting SpO2 of 88–92%) [18]. The British Thoracic Society rec-
ommends that oxygen should be prescribed to achieve a target saturation of 94–98% for 
most acutely ill patients, with a patient-specific target saturation of 88–92% for patients at 
risk of type II (hypercapnic) respiratory failure [19], and the Surviving Sepsis Campaign 
guidelines recommend a target SpO2 of 92–96% [20]. However, oxygenation goals for pa-
tients with severe illness and respiratory symptoms should always depend intrinsically 
on underlying factors, and liberal oxygen treatment may increase the risk of mortality in 
patients with acute cerebral or coronary ischemia [21], as well as in those in ICUs [22]. 
The World Health Organization recommends a target SpO2 of ≥90% for nonpregnant 
(≥92–95% for pregnant) patients with COVID-19-associated ARF and also recommends 
reaching these targets by titration via a nasal cannula, simple face mask, or a face mask 
with a reservoir bag [23] (Figure 1). Studies on optimal target oxygenation in patients with 
COVID-19-associated ARF are scarce, and no RCTs have been performed to the best of 
our knowledge. An additional challenge on this subject is the traditional mode of prescrib-
ing oxygen therapy, which is often not documented or specified to the degree, which is 
common with pharmaceutical therapies [24]. Patients with COVID-19-associated ARF, de-
spite the provision of maximal oxygen levels via a face mask, should be promptly identi-
fied and evaluated with a view to providing respiratory support via HFNC, CPAP, or 
intubation and mechanical ventilation [25] (Figure 1). 
 
Figure 1. Flowchart for the treatment of type 1 respiratory failure. SpO2 = peripheral oxygen satura-
tion, FiO2 = fraction of inspired oxygen, PaCO2 = partial pressure of carbon dioxide in arterial blood, 
cCPAP = continuous (i.e., nonintermittent) continuous positive airway pressure, HFNC = high-flow 
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nasal cannula oxygen therapy, IMV = invasive mechanical ventilation, BiPAP = bilevel positive air-
way pressure, COPD = chronic obstructive pulmonary disease, COVID-19 = coronavirus disease 
2019. Adapted from Nielsen Jeschke K. et al. 2020 [25]. 
4. Diagnosing Acute Respiratory Failure 
In hypoxemic (type I) respiratory failure patients are diagnosed by a peripheral sat-
uration measurement or preferably an arterial gas analysis. Hypoxemic respiratory failure 
is defined as a lowered PaO2 or SpO2 measurement (hypoxemia) with either a standard 
(normocapnia) or low (hypocapnia) PaCO2 measurement. For a certain diagnosis of res-
piratory failure, PaO2 < 60 mmHg by arterial gas analysis is mandatory. 
In patients with COVID-19-associated ARF, the PaO2/FiO2 ratio was able to predict 
severity in a cohort of 421 patients [26], as well as in a smaller cohort of 150 patients. In 
the latter cohort, the authors were able to calculate an optimal cut-off PaO2/FiO2 ra-
tio of 274 mmHg, which could distinguish between patients with mild disease and pa-
tients with severe disease with a sensitivity of 72% and specificity 85% [27], and it also 
contributed to a predictive composite score along with age, platelets, pH, blood urea ni-
trogen, temperature, PaCO2, and Glasgow Coma Scale in a cohort of 937 patients [28]. 
A study has examined an algorithm for predicting COVID-19-associated ARDS 
among 964 patients who would develop ARDS within 12 h, as compared to 4712 patients 
who did not. The machine algorithm found that the two most important predictive factors 
for the development of COVID-associated ARDS were saturation in the shape of the low-
est measured SpO2 and standard deviation of measured SpO2. This was complemented by 
age, maximal FiO2, maximal respiratory rate, and maximal and standard deviation O2 
flow. Hence, and perhaps not surprising, several different respiratory measures seem to 
contribute substantially to predicting ARDS in patients with COVID-19. However, as a 
possible future biomarker, the lowest measured platelet count also contributed to the al-
gorithm [29] 
In patients without COVID-19, several biomarkers seem promising in diagnosing 
and predicting the development of ARF, and some have already to some degree proven 
their value. Plasma surfactant protein D (SP-D) has been shown to increase within 48 h of 
admission to ICU in patients who developed ARDS and to predict the long-term need for 
IMV and mortality [30–32], and angiopoietin-2 was able to predict pulmonary affection in 
cohort studies in critically ill patients with various underlying courses [33–36] and also 
predict severity of illness and mortality [37–40]. 
Among patients with COVID-19, a cohort study of 259 patients found that SOFA 
score and ROX index predicted HFNC failure to IMV [41], and in a small cohort, male sex, 
obesity, African American ethnicity, comorbidities, and prior immunosuppression pre-
dicted HFNC failure and need for IMV [42], though in this small study, no biomarker was 
able to predict a respiratory worsening [42]. A retrospective cohort study of 610 patients 
showed a compound of age, history of coronary heart disease, CRP, aspartate aminotrans-
ferase, D-dimer, and neutrophil-to-lymphocyte ratio was able to form an acceptable ROC 
curve [43], and in a retrospective cohort study of 638 patients, CRP, neutrophil-to-lym-
phocyte ratio, and D-dimer were associated with adverse events, such as acute myocardial 
injury, respiratory failure, acute kidney injury, mechanical ventilation, intensive care unit 
admission, multiple organ dysfunction syndromes, and death [44].  
Elevated levels of LDH have also been associated with severity [45,46], and in a co-
hort study of 100 patients, ferritin was able to predict in-hospital mortality with a superior 
ROC curve to CRP [47], and in a cohort of 153 patients, severity of disease was associated 
with plasma levels of interleukin-6 (IL-6), CRP, soluble-IL2 receptor (IL2Rα), procalci-
tonin (PCT), and ferritin [48]. IL-6 has also been shown to correlate to SpO2 and PaO2 in 
48 patients, and it correlated well with CRP in these patients [49]. This is not in contrast 
to studies on patients with ARF without COVID-19; however, in this context, IL-6 was a 
somewhat inconsistent predictor of ARF, ARDS, severity, and mortality [37,38,50–52]. 
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Similarly, PCT has in patients without COVID-19 been a poor indicator for need for anti-
biotic treatment [53]. 
5. Continuous Positive Airway Pressure 
CPAP is a positive airway pressure therapy that delivers a set pressure of airflow to 
the airways. The C for continuous in CPAP refers to the constant pressure, which is main-
tained throughout the respiratory cycle, both when the person is breathing in (inspiration) 
and breathing out (expiration). This therapy can be administered for prolonged periods 
of time, referred to as continuously administered CPAP (cCPAP), or for very short time 
intervals, referred to as intermittently administered CPAP. In this review, we only discuss 
cCPAP therapy.  
A CPAP device consists of a unit that generates airflow, which is delivered to the 
airway through either a helmet or face mask, and the effects of CPAP have been studied 
in more than 1100 patients with ARF due to COVID-19 pneumonia [3]. Continuous ther-
apy with CPAP for COVID-19-associated ARF may be considered when a patient with 
hypoxic respiratory failure requires 6–15 L/min oxygen (i.e., fraction of inspired oxygen 
(FiO2), 0.4–0.6) to achieve an acceptable level of oxygen saturation, and clinicians agree 
that escalation to IMV would be an option, but it is not immediately necessary (Figure 1). 
When commencing the CPAP therapy, an initial pressure of 10–12 cm H2O may be ap-
plied, because positive end-expiratory pressure should be high, as in other cases of severe 
ARF [25,54,55]. Usually, CPAP therapy has an almost instantaneous effect on improving 
the condition of patients with COVID-19-associated ARF; however, if more oxygen is nec-
essary, then intubation and IMV may be required [25].  
The RECOVERY-RS trial, led by the University of Warwick and Queen’s University 
Belfast, is the world’s largest noninvasive respiratory support trial for COVID-19, with 
over 1200 participants taking place across 48 United Kingdom hospitals. This multicenter 
adaptive RCT compared the use of CPAP (oxygen and positive pressure delivered via a 
tightly fitting mask), HFNC, and standard care (standard oxygen therapy). The results 
showed that treating hospitalized COVID-19 patients who had ARF with continuous 
CPAP reduced the need for IMV [56]. In the CPAP group, 137 of 377 participants (36.3%) 
either needed mechanical ventilation or died within 30 days, compared with 158 of 356 
participants (44.4%) in the conventional oxygen therapy group (unadjusted odds ratio, 
0.72; 95% confidence interval (CI), 0.53 to 0.96; p = 0.03). However, there was a small in-
crease in the number of serious adverse events with CPAP compared with conventional 
oxygen therapy [56]. On the other hand, one small RCT and several cohort studies have 
shown that continuous CPAP therapy is not successful for all patients, and failure rates 
are higher when the treatment ceiling excludes IMV, such as when treating elderly pa-
tients who have many comorbidities [55,57–62]. Continuous CPAP has particularly bene-
ficial effects on respiratory rate and oxygenation levels, and the majority of patients with 
COVID-19 who are offered continuous CPAP therapy (83–97%) are able to tolerate the 
treatment [57,63]. CPAP weaning may be undertaken reasonably safely (83% success rate) 
after treatment has successfully improved respiratory performance and the modified ROX 
index (PaO2/FiO2/respiratory rate) has increased to 8.4 mm Hg/bpm [62]. Initial 6-month 
follow-up studies of survivors of COVID-19-associated ARF treated with continuous 
CPAP were optimistic concerning respiratory parameters and exercise capacity [64]. 
6. Bilevel Positive Airway Pressure 
BiPAP ventilates by applying positive pressure into the lungs through a mask or a 
helmet [38]. BiPAP can be used as initial treatment, followed by a step up to IMV if 
needed, or as a method for weaning patients off IMV. BiPAP is very effective, and many 
guidelines describe BiPAP as the first-line treatment for ARF caused by acute exacerba-
tions of chronic obstructive pulmonary disease or acute cardiogenic pulmonary edema 
[65,66]. One study investigated the efficacy of BiPAP in treating ARF resulting from vari-
ous etiologies [67]. The highest BiPAP failure rate was among patients with hypoxemic 
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respiratory failure, and the lowest was among patients with acute pulmonary edema [41]. 
Previous studies have shown that BiPAP can effectively treat viral pneumonia with hy-
poxic respiratory failure. Failure rates were as low as approximately 30%. For influenza 
A (H1N1), the failure rate was 13–77% [66]. Potential difficulties associated with BiPAP 
treatment include low patient compliance, claustrophobia, dyspnea, and development of 
skin rashes [6,68].  
BiPAP may be used to treat COVID-19-associated ARF at an initial inspiratory pres-
sure of 20 cm H2O and an expiratory pressure of 10 cm H2O combined with low tidal 
volumes such as 4–8 mL/kg [25,54]. The HENIVOT trial, a multicenter RCT of 110 patients 
(median age, 65 years), evaluated whether helmet BiPAP for two days followed by HFNC 
therapy was superior to HFNC alone. Though the primary outcome was not met, among 
the secondary outcomes, the rate of endotracheal intubation was significantly lower in the 
BiPAP group than in the HFNC group (30% vs. 51%; p = 0.03). These data are obviously 
not conclusive, and the area needs further investigation [69]. As with CPAP treatment, 
age, comorbidities, and the severity of the disease predicted BiPAP treatment failure and 
mortality in patients with COVID-19-associated ARF [70,71]. Treating patients who are in 
the prone position with BiPAP has produced promising results; however, the relevant 
data are limited because few patients are initially treated in the prone position [72,73]. 
Overall, BiPAP failure rates ranged from 48 to 53% [70,71]. Finally, BiPAP has been used 
as a step-down measure from IMV, with BiPAP being implemented immediately after 
early extubation in patients with severe COVID-19-associated ARF. This strategy reduced 
the duration of intubation, the extubation failure rate, and the need for reintubation. How-
ever, patients treated with BiPAP had also been given more antiviral agents and more 
corticosteroids. Larger studies are needed to verify the few preliminary data on these Bi-
PAP strategies. Both CPAP and BiPAP treatment are associated with a considerable risk 
of complications such as pneumothorax/pneumomediastinum, hemodynamic instability, 
and delirium and require careful monitoring [56,57,74]. These risks may be increased 
among patients suffering from COVID-19-associated ARF [75]. 
7. High-Flow Nasal Cannula Oxygen Therapy 
HFNC involves the delivery of a high flow of warm humidified oxygen (up to 60 
L/min) through a small nasal cannula, improving oxygenation and reducing respiratory 
rates, as well as providing higher concentrations of oxygen than therapy with supple-
mental oxygen alone [76,77]. In patients who did not have COVID-19, the European Res-
piratory Society (ERS) recommends HFNC therapy to patients with hypoxic respiratory 
failure over conventional nasal cannula therapy and NIV; however, they do not recom-
mend HFNC over NIV in patients at high risk of extubation failure, in patients with 
chronic obstructive pulmonary disease (COPD), or in patients with hypercapnic ARF [78]. 
Treatment with HFNC resulted in similar mortality rates but less frequent intubation, 
compared to patients treated with conventional oxygen therapy [79], and HFNC is usually 
tolerated quite well [80].  
Preliminary data from a recent RCT involving HFNC treatment of COVID-19 pa-
tients with ARF (n = 1272) suggested that routine use of HFNC did not improve patient 
outcomes, compared with conventional oxygen therapy. The RCT did not find any bene-
fits associated with using HFNC rather than conventional oxygen therapy. A total of 184 
of 414 participants who received HFNC (44.4%) vs. 166 of 368 participants who received 
conventional oxygen therapy (45.1%) met the composite endpoint of tracheal intubation 
or death within 30 days (unadjusted odds ratio, 0.97; 95% CI, 0.73 to 1.29; p = 0.85), whereas 
continuous CPAP was superior to conventional oxygen therapy [56]. Therefore, routinely 
offering HFNC as the main form of respiratory support for patients with respiratory fail-
ure due to COVID-19 is not recommended [81], but HFNC may be suitable for patients 
who need a break from CPAP (e.g., at mealtimes) or for patients who are being weaned 
off CPAP or need humidified oxygen or for patients who cannot tolerate CPAP. As de-
scribed above, evidence from the HENIVOT trial [69] suggests that for COVID-19 patients 
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with moderate-to-severe hypoxemia, treatment with helmet noninvasive ventilation did 
not increase the number of days free of respiratory support within 28 days, compared 
with high-flow nasal oxygen (mean difference, 2 days; 95% CI, –2 to 6; p = 0.26). In addi-
tion, helmet noninvasive ventilation followed by HFNC significantly reduced the number 
of patients who needed invasive ventilation, compared with HFNC alone. Previous small 
national studies on clinical outcomes in patients with COVID-19 who were treated with 
HFNC were mostly uncontrolled and retrospective and did not reach definitive conclu-
sions [82–84]. This may be partly due to confounding variables and biases, as well as the 
difficulties associated with extrapolating results from one population to another. In addi-
tion, some of these studies primarily had exploratory relevance in the earlier stages of the 
SARS-CoV-2 pandemic. Looking at the use of HFNC from another point of view, a retro-
spective study of patients with COVID-19 who developed ARF found that 41% of those 
treated with HFNC experienced treatment failure and required BiPAP or intubation. The 
HFNC treatment failure rate was highest among patients with low PaO2/FiO2 ratios. This 
marker is frequently used in intensive care settings and may help to identify those patients 
with COVID-19 and ARF who are most likely to require escalation in therapy from HFNC 
[85]. Further research is needed to clarify particular aspects of HFNC, including treatment 
targets, safety, efficacy, and how it should be administered to patients with ARF and 
COVID-19. 
8. Prone Positioning 
Positioning as a therapy method in non-ICU patients with COVID-19-associated ARF 
has also been examined to better oxygenate and avoid IMV. So far, studies on positioning 
in non-ICU patients have been conducted with prone positioning undertaken only during 
waken periods. Two small RCTs have been conducted so far. An RCT feasibility study of 
60 patients with hypoxic ARF secondary to COVID-19 pneumonia found no effect of 
prone position on the need for additional respiratory therapy or mortality; however, only 
13 patients encouraged to lay in the prone position were able to self-prone for at least 6 h 
a day. In the standard care group, 16 patients chose by themselves to spend time in the 
prone position, which may have masked an effect [86]. A pilot trial designed as a cluster 
study in a quaternary care center included five inpatient medical service teams to either 
encourage prone positioning or standard care with no randomization of patients found 
no effect on oxygen saturation to fraction of inspired oxygen ratio of encouragement of 
medical service teams to prone positioning [87]. Finally, a small cohort study of 20 patients 
examined peripheral oxygen saturation and showed an improvement from 96% in the 
supine position to 98% in the prone position (p = 0.008). However, the patients reported 
worsening in comfort score [88]. Hence, any effect of prone positioning in non-ICU pa-
tients remains to be shown but can also not be rejected with the currently available evi-
dence. 
9. Stepping up the Therapeutic Regimens 
A retrospective observational study [89] investigated moderate-to-severe ARDS as-
sociated with COVID-19 and studied a treatment regimen in which supplemental oxygen 
was provided, followed by BiPAP/CPAP if oxygen saturation levels and respiratory rates 
did not improve. This was followed by IMV if signs of BiPAP failure were observed, such 
as worsening of dyspnea or hypoxemia, respiratory acidosis, or circulatory shock. The 
authors found that BiPAP was associated with a lower association with IMW therapy. 
Two studies showed a benefit of a stepwise approach. The recommended approach begins 
with HFNC as the first-line treatment. If oxygen saturation levels decrease and respiratory 
rates increase to >30/min, treatment should be escalated to BiPAP or CPAP. Subsequently, 
intubation is indicated if parameters that are used to monitor the patient’s condition 
worsen. These two papers suggest a strategy in which HFNC, BiPAP, and IMV are all 
involved at different stages of ARF depending on the status of the patient [12,89]. 




BiPAP, CPAP, and HFNC may be beneficial alternatives to IMV for COVID-19-asso-
ciated ARF. One large, comprehensive RCT [56] has shown that continuous CPAP is su-
perior to conventional oxygen therapy delivered by binasal cannula; however, HFNC did 
not prove superior to oxygen therapy by binasal cannula. Thus, continuous CPAP should 
be preferred for patients with COVID-19-associated ARF if nasal catheter oxygen therapy 
is insufficient for adequate oxygenation, and IMV is not indicated. HFNC therapy can be 
used if CPAP is not tolerated. For patients with COVID-19-associated ARF, a stepwise 
treatment approach that is based on patient status and includes several consecutive ven-
tilation strategies may be the way forward. 
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